Supplementary Materials

Supplementary Material for:

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

Takahiro Ishiguro, Yuji Sano, Shun-ichiro Komatsu, Mika Kamata-Sakurai, Akihisa Kaneko, Yasuko Kinoshita, Hirotake Shiraiwa, Yumiko Azuma, Toshiaki Tsunenari, Yoko Kayukawa, Yukiko Sonobe, Natsuki Ono, Kiyoaki Sakata, Toshihiko Fujii, Yoko Miyazaki, Mizuho Noguchi, Mika Endo, Asako Harada, Werner Frings, Etsuko Fujii, Eitaro Nanba, Atsushi Narita, Akihisa Sakamoto, Tetsuya Wakabayashi, Hiroko Konishi, Hiroaki Segawa, Tomoyuki Igawa, Takashi Tsushima, Hironori Mutoh, Yukari Nishito, Mina Takahashi, Lorraine Stewart, Ehab ElGabry, Yoshiki Kawabe, Masaki Ishigai, Shuichi Chiba, Masahiro Aoki, Kunihiro Hattori, Junichi Nezu*

*Corresponding author. Email: nezujyn{at}chugai-pharm.co.jp

Published 4 October 2017, Sci. Transl. Med. 9, eaal4291 (2017)
DOI: 10.1126/scitranslmed.aal4291

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Cancer cell growth inhibition induced by ERY974.
  • Fig. S2. TDCC and polyclonal T cell activation induced by ERY974 targeting cancer cell lines.
  • Fig. S3. Plasma concentration–time profiles of ERY974 after a single intravenous administration.
  • Fig. S4. Influence of DEX pretreatment on the antitumor efficacy of ERY974 at a dose with submaximal efficacy (0.04 mg/kg).
  • Table S1. H-scores for 31 hepatocellular carcinoma TMA cores staining for GPC3.
  • Table S2. H-scores for 40 lung squamous cell carcinoma TMA cores staining for GPC3.
  • Table S3. H-scores for 69 lung small cell carcinoma TMA cores staining for GPC3.
  • Table S4. H-scores for 87 esophagus squamous cell carcinoma TMA cores staining for GPC3.
  • Table S5. H-scores for 30 cardiac adenocarcinoma TMA cores staining for GPC3.
  • Table S6. H-scores for 40 gastric cancer TMA cores staining for GPC3.
  • Table S7. H-scores for 68 head and neck cancer TMA cores staining for GPC3.
  • Table S8. H-scores for 30 different normal TMA cores staining for GPC3.
  • Table S9. Histopathological analysis of Hepa1-6/hGPC3 and LLC1/hGPC3 tumors.
  • References (52, 53)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S10. (Microsoft Excel format). Primary data.